Background
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies, with a 5-year survival rate of less than 10%. Despite advances in chemotherapy, the majority of patients with unresectable advanced PDAC develop resistance to treatment, leading to poor outcomes. The mechanisms underlying this chemoresistance are poorly understood, particularly how chemotherapy remodels the tumor microenvironment (TME) and tumor cell plasticity.
Study Design
The study by Zhang et al. employed single-cell RNA sequencing (scRNA-seq) on paired pre- and post-treatment tumor biopsies and peripheral blood mononuclear cells (PBMCs) from 28 patients with PDAC receiving abraxane plus gemcitabine chemotherapy. Multiplex immunofluorescence and spatial transcriptomics were used to validate findings at high resolution. Functional validation included CRISPR-Cas9 knockout, tumor-killing assays, and in vivo studies using the KPC mouse model and xenograft tumors.
Key Findings
Chemotherapy-Induced Remodeling
The study revealed dynamic remodeling of malignant states and the immune microenvironment during chemotherapy. A chemoresistant niche was identified, composed of SNCG+ basal-like tumor cells, SPP1+ tumor-associated macrophages (TAMs), and exhausted T cells, which predominated in nonresponders.
Role of CD276/B7-H3
CD276/B7-H3 emerged as a dual-function immune checkpoint. It not only promoted tumor transition to a chemoresistant basal-like state but also induced T cell exhaustion and enhanced angiogenesis in TAMs. Functional assays confirmed that CD276 knockout sensitized tumor cells to chemotherapy, while its overexpression conferred resistance.
Expert Commentary
This study provides unprecedented insights into the cellular and molecular mechanisms of chemoresistance in PDAC. The identification of CD276 as a key regulator offers a promising therapeutic target. However, the translational potential of these findings will require further validation in larger cohorts and clinical trials.
Conclusion
The findings underscore the plasticity of PDAC tumor cells and their interactions with the TME during chemotherapy. Targeting CD276/B7-H3 may represent a novel strategy to overcome chemoresistance and improve outcomes in advanced PDAC. Future research should explore combination therapies targeting both tumor cells and the immune microenvironment.
Funding and ClinicalTrials.gov
This study was supported by grants from the National Natural Science Foundation of China. The clinical trial registration number was not provided in the original publication.
References
Zhang Y, Du Y, Wang J, et al. Single-Cell Analysis of Chemotherapy-induced Remodeling Reveals CD276-driven Basal-like Chemoresistance in Pancreatic Cancer. Gastroenterology. 2026;170(4):769-786. PMID: 41701125.
